

CQLabs
MicroCBD™
(cannabidiol xs) capsules
 USPTO Patent Pending

DESCRIPTION


MicroCBD™, for oral administration, contains a patent-pending form of water-soluble, nano-emulsified cannabidiol.

MicroCBD™ is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is soluble in water as well as oil.

The chemical name for cannabidiol is:

2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol.
 Its molecular formula is C₂₁H₃₀O₂, and the molecular weight is 314.469 g/mol.

The structural formula is represented below:




MicroCBD™ patent-pending form of cannabidiol is available in multiple strengths: (8mg/capsule, 16mg/capsule, 62.5mg/capsule).

Each MicroCBD™ capsule contains:

- Cannabidiol
- Excipients
- Proprietary Biomarkers
- Proprietary CBDelivery System™

Bioavailability of MicroCBD™ vs. Standard CBD's
(cannabidiol) capsules



HOW SUPPLIED

MicroCBD Capsules are available as follows:

- 8 mg Capsule 30 count bottle
- 8 mg Capsule 60 count bottle
- 16 mg Capsule 30 count bottle
- 16 mg Capsule 60 count bottle
- 62.5 mg Capsule 30 count bottle

Bottles should be stored at controlled room temperature 15 to 30 C (59 - 86 F).

Protect from heat, light, and moisture.

This product's label may have been updated. For current information, please visit CQLabs.com

DOSAGE AND ADMINISTRATION

Prior to initiating MicroCBD™ (Cannabidiol), consult your healthcare professional.

MicroCBD™ is for oral administration only.

The suggested dosage for MicroCBD™ Capsules varies depending on the age, sex, and diagnosis of the individual patient. Dosage is adjusted based on the patient's response and any appearance of adverse reactions.

OVERDOSAGE

There have been no reports of overdosage with cannabidiol.

DEPENDENCE

Behaviors Associated with Addiction

Continued abuse of cannabidiol and other cannabidiols, leading to addiction is characterized by the following behaviors:

- Taking cannabidiol dosages greater than recommended
- Giving a higher priority to cannabidiol use than to other obligations
- Continued cannabidiol use despite medical and social issues due to use
- Spending excessive amounts of time trying to obtain cannabidiol
- Inability to discontinue use despite multiple attempts

Individuals taking supratherapeutic doses of cannabidiol may experience withdrawal symptoms. These withdrawals may include but are not limited to craving, restlessness, irritability, insomnia, and anxiety.

Dependence in individuals using recommended doses of cannabidiol for recommended indications has not been documented.

Information for patients

Patients should be instructed to report any of the following: nausea, vomiting, changes in skin color, swelling, and or any other abnormal conditions after starting treatment.

Laboratory tests

Cannabidiol levels should be checked periodically in patients receiving long-term cannabidiol administration.

The CQLabs CBDelivery System™

Oral administration of cannabidiol is already proven effective for many conditions. However bioavailability is a major concern. The CQLabs proprietary CBDelivery System™ has addressed this precise issue. The CQLabs CBDelivery System™ has increased the bioavailability by a factor of 3-4x. This enables patients to administer and process less cannabidiol and at the same time obtain greater results.

Exclusively Manufactured for and Distributed by:

CQLabs
 Clinical Quality Labs

www.CQLabs.com



Non Rx
 30 CAPSULES

CQLabs
MicroCBD™
(cannabidiol xs) capsules

Clinical Strength
 8 mg / 16 mg / 62.5 mg

ATTENTION NATURAL PRODUCT USER:
 This Patent Pending Formulation differs
 clinically tested CBD's as an ingredient.
 The Patent Pending CBD's in this product may
 be 3X or more the strength of standard CBD's.

Keep MicroCBD in the original container.
 Protect from light, heat and moisture.
 Do not use if safety seal is broken.